|
Daiichi Sankyo Company, Limited announced that it has launched Delytact (teserpaturev/G47?), an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo.
Delytact received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma (a type of malignant glioma) conducted by Dr. Todo.
For the time being, Delytact will be commercially available only at hospitals that served as trial sites. Daiichi Sankyo will establish a stable supply system of the medicine as soon as possible.
Daiichi Sankyo to offer Delytact as a new option for the treatment of malignant glioma and to contribute to the high unmet medical needs of patients suffering from this brain cancer.
Delytact (teserpaturev/G47?) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1) developed by Dr Todo and his colleagues. Delytact has triple mutations within the viral genome that cause augmented and selective replication in cancer cells (third generation oncolytic HSV-1).
Glioblastoma is highly malignant glioma (grade IV) and found in approximately 60% to 70% of patients with malignant glioma.
The oncology portfolio of Daiichi Sankyo is powered by our team of world-class scientists that push beyond traditional thinking to create transformative medicines for people with cancer. Anchored by its DXd antibody drug conjugate (ADC) technology, our research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., its small molecule structure-guided R&D center in the U.S. We also work alongside leading academic and business collaborators to further advance the understanding of cancer as Daiichi Sankyo builds towards its ambitious goal of becoming a global leader in oncology by 2025.
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging its world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.
|